1

### Description

The SMURF1 Intrachain TR-FRET Assay Kit is a sensitive high-throughput screening (HTS) TR-FRET (Time Resolved Fluorescence Resonance Energy Transfer) assay kit, designed to measure SMURF1 (SMAD ubiquitination regulatory factor 1) auto-ubiquitination activity in a homogeneous 384 reaction format. It utilizes a Europium cryptate-labeled Ub (donor) as well as Cy5-labeled Ub (acceptor) to complete the TR-FRET pairing. Since both the TR-FRET donor and acceptor are incorporated into poly-ubiquitin chains formed on SMURF1, this FRET-based assay requires no time-consuming washing steps, making it especially suitable for HTS applications as well as real-time kinetics analyses of polyubiquitination. This kit contains enough recombinant human SMURF1 (amino acids 150-end) and reagents for 384 reactions.




Figure 1. SMURF1 Intrachain TR-FRET Assay Kit schematic.

#### Background

Covalent conjugation to ubiquitin (Ub) is one of the major post-translational modifications that regulates protein stability, function, and localization. Ubiquitination is the concerted action of three enzymes: a Ub-activating enzyme (E1), a Ub-conjugating enzyme (E2), and a Ub ligase (E3). The specificity and efficiency of ubiquitination are largely determined by the E3 enzyme, which directs the last step of the Ub-conjugating cascade by binding to both an E2~Ub conjugate and a substrate protein. This step ensures the transfer of Ub from E2~Ub to the substrate, leading to its mono- or poly-ubiquitination.

The SMAD ubiquitination regulatory factor 1 (SMURF1) is a HECT-type E3 Ub ligase that regulates TGF- $\beta$ /BMP pathways via ubiquitination of key signal transducers (SMAD1, SMAD2, or SMAD5), or TGF- $\beta$  receptor I. Like most E3 ligases, SMURF1 ubiquitinates itself. SMURFs play a critical role in cell-type specification, tissue and organ development by regulating planar cell polarity signaling and convergent extension. SMURFs can also accelerate tumor progression, invasion, and metastasis as they regulate ubiquitination and subsequent proteasomal degradation of tumor-suppressing proteins including p53 as well as various cell signaling proteins. That is why SMURF1 and especially its Ub ligase activity is an attractive potential drug target in cancer immunotherapy.

### Applications

- Screen molecules that inhibit SMURF1 Ub ligase activity in drug discovery HTS applications.
- Determine compound IC<sub>50.</sub>
- Perform SMURF1 real-time kinetics analyses.



| eappilea ma |  | 1         | 1         |
|-------------|--|-----------|-----------|
| Catalog #   | Name   | Amount    | Storage   |
| 80301       | UBE1 (UBA1), FLAG-Tag *                        | 2 x 25 μg | -80°C     |
| 80314       | UbcH5b, His-Tag*                               | 60 µg     | -80°C     |
| 80402       | SMURF1, FLAG-Tag*                              | 20 µg     | -80°C     |
| 78307       | TRF Ubiquitin Mix (200x)                       | 40 µl     | -80°C     |
|             | ATP (4 mM)                                     | 2 x 1 ml  | -80°C     |
|             | U2 Assay Buffer                                | 2 x 10 ml | -80°C     |
| 79969       | White, nonbinding, low volume microtiter plate |           | Room Temp |

#### **Supplied Materials**

\* The initial concentration of enzyme is lot-specific and will be indicated on the tube containing the protein.

The Ubiquitin Mix is sourced from South Bay Bio LLC.

# **Materials Required but Not Supplied**

- Fluorescent microplate reader capable of measuring Time Resolved Fluorescence Resonance Energy Transfer (TR-FRET)
- Adjustable micropipettor and sterile tips
- Rotating or rocker platform

### **Storage Conditions**

This assay kit will perform optimally for up to **6 months** from date of receipt when the materials are stored as directed. *Avoid multiple freeze/ thaw cycles!* 

### Safety



This product is for research purposes only and not for human or therapeutic use. This product should be considered hazardous and is harmful by inhalation, in contact with skin, eyes, clothing, and if swallowed. If contact occurs, wash thoroughly.

### Contraindications

The SMURF1 Intrachain TR-FRET Assay Kit is compatible with up to 1% final DMSO concentration. We recommend preparing the inhibitor in a solution containing no higher than 5% DMSO and using 4  $\mu$ l per well.

### **Assay Protocol**

- All samples and controls should be performed in triplicate.
- The assay should include "Blank", "Positive Control", "Negative Control" and "Test Compound" conditions.
- If the assay plate is going to be used more than once, prepare enough of each protein and buffer and aliquot the remaining undiluted proteins into single-use aliquots depending on how many times the assay plate will be used. Store the aliquots at -80°C.



- 1) Thaw UBE1, UbcH5b, SMURF1, TRF Ubiquitin Mix, U2 Assay Buffer, and ATP on ice. Briefly spin the tubes to recover their full content.
- 2) Prepare 5x TRF Ubiquitin Mix in U2 Assay Buffer by making a 40-fold dilution of the stock TRF Ubiquitin Mix (200x).
- 3) Calculate the amount of protein required for the assay and prepare the appropriate amounts of diluted proteins. The concentration of each protein is lot-specific and is indicated on the tube. Verify the initial concentration and dilute accordingly.
  - a) Dilute UBE1 in U2 Assay Buffer to 96 ng/ $\mu$ l (800 nM final concentration in reaction 40 nM) (1  $\mu$ l/well).
  - b) Dilute UbcH5b in U2 Assay Buffer to 144 ng/µl (8  $\mu$ M final concentration in reaction 400 nM) (1  $\mu$ l/well).
  - c) Dilute SMURF1 in U2 Assay Buffer to 7 ng/ $\mu$ l (100 nM final concentration in reaction 25 nM) (5  $\mu$ l/well).

Note: UBE1, UbcH5b, SMURF1, TRF Ubiquitin Mix, and U2 Assay Buffer are sensitive to freeze/thaw cycles. Avoid multiple freeze-thaw cycles. Keep all diluted proteins on ice until use.

- 4) Prepare the Test Compound (4  $\mu$ l/well): for a titration prepare serial dilutions at concentrations 5-fold higher than the desired final concentrations. The final volume of the reaction is 20  $\mu$ l.
  - a) If the Test Compound is water-soluble, prepare serial dilutions in the U2 Assay Buffer, 5-fold more concentrated than the desired final concentrations. For the positive and negative controls, use U2 Assay Buffer (Diluent Solution).

### OR

b) If the Test Compound is soluble in DMSO, prepare the test compound in 100% DMSO at a concentration 100-fold higher than the highest desired concentration, then dilute the compound 20-fold in U2 Assay Buffer to prepare the highest concentration of the 5-fold intermediate dilutions. The concentration of DMSO is now 5%.

Prepare serial dilutions of the Test Compound at 5-fold the desired final concentrations using 5% DMSO in U2 Assay Buffer to keep the concentration of DMSO constant.

For positive and negative controls, prepare 5% DMSO in U2 Assay Buffer (vol/vol) so that all wells contain the same amount of DMSO (Diluent Solution).

Note: The final concentration of DMSO should not exceed 1%.

5) For the "Blank" wells prepare the following mix: N wells X (4  $\mu$ l of 5x TRF Ubiquitin Mix + 1  $\mu$ l of diluted UBE1 + 1  $\mu$ l of diluted UbcH5b + 4  $\mu$ l of Diluent Solution + 5  $\mu$ l of U2 Assay Buffer).



3

6) Add 15 µl of mix to each "Blank" well.

|                        | Blank |
|------------------------|-------|
| TRF Ubiquitin Mix (5x) | 4 μl  |
| Diluted UBE1           | 1 µl  |
| Diluted UbcH5b         | 1 µl  |
| Diluted SMURF1         | -     |
| Test Compound          | -     |
| Diluent Solution       | 4 μl  |
| U2 Assay Buffer        | 5 µl  |
| ATP (4 mM)             | 5 µl  |
| Total                  | 20 µl |

i.

- 7) Prepare a Master Mix: N wells × (4  $\mu$ l 5x TRF Ubiquitin Mix + 1  $\mu$ l diluted UBE1 + 1  $\mu$ l diluted UbcH5b + 5  $\mu$ l diluted SMURF1).
- Add 11 μl of Master Mix to each well designated "Negative Control", "Positive Control" and "Test Compound".
- 9) Add 4  $\mu$ l of compound solution to each well designated "Test Compound".
- 10) Add 4  $\mu$ l of the Diluent Solution to the "Positive Control" and "Negative Control" wells.
- 11) Initiate the reaction by adding 5  $\mu$ l of ATP to the wells labeled "Positive Control", "Test Compound", and "Blank".
- 12) Add 5 µl of U2 Assay Buffer to the wells designated "Negative Control".

|                  | Test<br>Compound | Negative<br>Control | Positive<br>Control |
|------------------|------------------|---------------------|---------------------|
| Master Mix       | 11 µl            | 11 µl               | 11 µl               |
| Test compound    | 4 μl             | -                   | -                   |
| Diluent Solution | -                | 4 µl                | 4 μl                |
| U2 Assay Buffer  | -                | 5 µl                | -                   |
| ATP (4 mM)       | 5 µl             | -                   | 5 µl                |
| Total            | 20 µl            | 20 µl               | 20 µl               |

- 13) Read the fluorescence intensity in a microtiter-plate reader capable of measuring TR-FRET in kinetic mode for up to 1 hour. An end point readout can be done in 20-40min.
- 14) "Blank" value should be subtracted from all other values.



# Instrument Settings

Two sequential measurements should be conducted. Eu-donor emission should be measured at 620 nm followed by dye-acceptor emission at 665 nm. Data analysis is performed using the TR-FRET ratio (665 nm emission/ 620 nm emission).

| Reading Mode          | Time Resolved |  |
|-----------------------|---------------|--|
| Excitation Wavelength | 317±20 nm     |  |
| Emission Wavelength   | 620±10 nm     |  |
| Lag Time              | 60 µs         |  |
| Integration Time      | 500 μs        |  |
| Excitation Wavelength | 317±20 nm     |  |
| Emission Wavelength   | 665±10 nm     |  |
| Lag Time              | 60 µs         |  |
| Integration Time      | 500 µs        |  |

# CALCULATING RESULTS:

Data analysis is performed using the TR-FRET ratio (665 nm emission/620 nm emission). "Blank" value is subtracted from all other values.

When percentage activity is calculated, the FRET value from the Blank (it is expected that Blank and Negative Control have a similar value) can be set as zero percent activity and the FRET value from the positive control can be set as one hundred percent activity.


% Activity =  $\frac{FRET_s - FRET_{blank}}{FRET_p - FRET_{blank}} x 100\%$ 

Where FRETs = Sample FRET, FRET<sub>blank</sub> = Blank FRET, and FRET<sub>P</sub> = Positive control FRET.



5

#### **Example Results**



SMURF1 TR-FRET Activity

Methyl-Ub, (Log [µM])

*Figure 2: Inhibition of SMURF1 auto-ubiquitination by Methylated Ubiquitin.* SMURF1 auto-ubiquitination was measured in the presence of increasing concentrations of Methylated Ubiquitin. Results are expressed as percent activity, in which absence of inhibitor is set to 100%.

Data shown is representative. For lot-specific information, please contact BPS Bioscience, Inc. at support@bpsbioscience.com.

#### **Troubleshooting Guide**

Visit bpsbioscience.com/assay-kits-faq for detailed troubleshooting instructions. For all further questions, please email support@bpsbioscience.com

| Products                              | Catalog # | Size          |
|---------------------------------------|-----------|---------------|
| Cereblon Intrachain TR-FRET Assay Kit | 78301     | 384 reactions |
| MDM2 Intrachain TR-FRET Assay Kit     | 78302     | 384 reactions |
| SMURF2 intrachain TR-FRET Assay Kit   | 78304     | 384 reactions |
| VHL intrachain TR-FRET Assay Kit      | 78305     | 384 reactions |
| XIAP intrachain TR-FRET Assay Kit     | 78306     | 384 reactions |
| MDM2 TR-FRET Assay Kit                | 79773     | 384 reactions |
| CBL-B TR-FRET Assay Kit               | 79575     | 384 reactions |
| c-CBL TR-FRET Assay Kit               | 79786     | 384 reactions |

